Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIA Clinical Trial of Intra-arterial Administration of Tirapazamine Followed by Transarterial Embolization （TATE）and KN046 for the Treatment of Advanced Colorectal Cancer with Liver Metastasis (MSS/pMMR)

NCT06834399 is registered in ClinicalTrials.gov with Zhejiang Raygene Pharmaceuticals Co., Ltd as lead sponsor.

NCT NCT06834399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06834399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIA Clinical Trial of Intra-arterial Administration of Tirapazamine Followed by Transarterial Embolization （TATE）and KN046 for the Treatment of Advanced Colorectal Cancer with Liver Metastasis (MSS/pMMR)
Lead sponsor
Zhejiang Raygene Pharmaceuticals Co., Ltd
Phase
Phase 2
Overall status
Terminated
Start date
April 27, 2023
Completion date
January 9, 2025
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer with hepatic metastases